PH12014501336A1 - Glucagon analogues - Google Patents
Glucagon analoguesInfo
- Publication number
- PH12014501336A1 PH12014501336A1 PH12014501336A PH12014501336A PH12014501336A1 PH 12014501336 A1 PH12014501336 A1 PH 12014501336A1 PH 12014501336 A PH12014501336 A PH 12014501336A PH 12014501336 A PH12014501336 A PH 12014501336A PH 12014501336 A1 PH12014501336 A1 PH 12014501336A1
- Authority
- PH
- Philippines
- Prior art keywords
- compounds
- treatment
- glucagon
- glucagon analogues
- glp
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 101500028775 Homo sapiens Glucagon Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579888P | 2011-12-23 | 2011-12-23 | |
| PCT/EP2012/076137 WO2013092703A2 (en) | 2011-12-23 | 2012-12-19 | Glucagon analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014501336A1 true PH12014501336A1 (en) | 2014-09-15 |
Family
ID=47594620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501336A PH12014501336A1 (en) | 2011-12-23 | 2014-06-11 | Glucagon analogues |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130316941A1 (en) |
| EP (1) | EP2793931A2 (en) |
| JP (1) | JP2015502380A (en) |
| KR (1) | KR20140114845A (en) |
| CN (1) | CN104144696A (en) |
| AP (2) | AP2014007797A0 (en) |
| AU (1) | AU2012357739A1 (en) |
| BR (1) | BR112014015681A2 (en) |
| CA (1) | CA2858949A1 (en) |
| EA (1) | EA201490982A1 (en) |
| HK (1) | HK1200369A1 (en) |
| IL (1) | IL232800A0 (en) |
| IN (1) | IN2014CN04401A (en) |
| MA (1) | MA35864B1 (en) |
| MX (1) | MX2014007120A (en) |
| PE (1) | PE20142113A1 (en) |
| PH (1) | PH12014501336A1 (en) |
| SG (1) | SG11201403377QA (en) |
| TN (1) | TN2014000224A1 (en) |
| WO (1) | WO2013092703A2 (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101809024B1 (en) | 2009-07-13 | 2017-12-14 | 질랜드 파마 에이/에스 | Acylated glucagon analogues |
| UY33462A (en) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | GLUCAGON ANALOGS |
| BR112012033225A2 (en) | 2010-06-24 | 2017-06-20 | Zealand Pharma As | glucagon analogs |
| AU2013255751B2 (en) | 2012-05-03 | 2017-10-05 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| EP2664374A1 (en) * | 2012-05-15 | 2013-11-20 | F. Hoffmann-La Roche AG | Lysin-glutamic acid dipeptide derivatives |
| CN109456400A (en) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | Glucagon analogue |
| TWI608013B (en) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | Glucagon analog |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| HRP20181300T1 (en) | 2012-12-21 | 2018-10-05 | Sanofi | Exendin-4 derivatives as dual glp1/gip/glucagon agonists |
| GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| AP2016009212A0 (en) | 2013-10-17 | 2016-05-31 | Zealand Pharma As | Acylated glucagon analogues |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Non-acylated EXENDIN-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| WO2016066744A2 (en) | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
| JOP20200119A1 (en) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | Gip and glp-1 co-agonist compounds |
| MA52253A (en) | 2015-02-17 | 2021-02-17 | Lilly Co Eli | NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA |
| CN107567459B (en) | 2015-03-18 | 2021-09-24 | 西兰制药公司 | Amylin analogs |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| KR20170137198A (en) * | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | Acylated glucagon analogs |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| AR105284A1 (en) | 2015-07-10 | 2017-09-20 | Sanofi Sa | DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS |
| TWI622596B (en) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | Glucagon receptor agonist |
| GB2566228A (en) | 2016-06-09 | 2019-03-06 | AmideBio LLC | Glucagon analogs and methods of use thereof |
| US9994591B2 (en) | 2016-08-05 | 2018-06-12 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| TWI784968B (en) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | Amylin analogues |
| KR102502040B1 (en) * | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | Acylated GLP-1/GLP-2 dual agonists |
| CN111094331B (en) * | 2017-08-16 | 2024-03-29 | 东亚St株式会社 | Acylated oxyntomodulin peptide analogues |
| JP7083397B2 (en) | 2018-02-02 | 2022-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Triazolopyrimidine derivative for use as a ghrelin O-acyltransferase (GOAT) inhibitor |
| EA202091804A1 (en) | 2018-02-02 | 2020-12-24 | Бёрингер Ингельхайм Интернациональ Гмбх | HETEROCYCLYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GRELIN-O-ACYLTRANSFERASE (GOAT) INHIBITORS |
| CR20200332A (en) | 2018-02-02 | 2020-09-03 | Boehringer Ingelheim Int | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| US11136337B2 (en) | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| CN111349155B (en) * | 2018-12-24 | 2022-04-05 | 浙江和泽医药科技股份有限公司 | Glucagon analogue and preparation method and application thereof |
| TWI771669B (en) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | Method for preparing stable peptide formulations |
| CN114641303A (en) | 2019-11-11 | 2022-06-17 | 勃林格殷格翰国际有限公司 | NPY2 receptor agonists |
| DK4153599T3 (en) | 2020-05-22 | 2024-06-17 | Boehringer Ingelheim Int | PROCEDURE FOR PREPARING ALKYL 7-AMINO-5-METHYL-[1,2,5]OXADIAZOLO[3,4-B]PYRIDINE CARBOXYLATE |
| ES2991340T3 (en) | 2020-05-22 | 2024-12-03 | Boehringer Ingelheim Int | Continuous process for the manufacture of alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridinecarboxylate |
| CN113278060B (en) * | 2020-05-29 | 2022-03-25 | 东莞云璟生物技术有限公司 | GLP-1/glucagon dual agonist fusion proteins |
| CA3185637A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0929567T3 (en) | 1996-09-09 | 2005-06-27 | Zealand Pharma As | Enhanced solid phase peptide synthesis and means for using such a synthesis |
| CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| SI1891105T1 (en) | 2005-06-13 | 2012-07-31 | Imp Innovations Ltd | Oxyntomodulin analogues and their effects on feeding behaviour |
| US7928058B2 (en) | 2006-02-22 | 2011-04-19 | Merck Sharp & Dohme Corp. | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition |
| EA020324B1 (en) | 2006-07-18 | 2014-10-30 | Санофи-Авентис | Antibodies against epha2 receptor and use thereof |
| BRPI0807728A2 (en) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | glucagon / glp-1 receptor co-agonists |
| WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| CN102123723B (en) | 2008-06-17 | 2016-05-25 | 印第安纳大学研究及科技有限公司 | Glucagon/GLP-1 receptor co-agonists |
| KR20110039230A (en) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Glucagon analogues showing enhanced solubility and stability in physiological ｐH buffer |
| JP5635532B2 (en) * | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | Glucagon analog |
| KR101809024B1 (en) * | 2009-07-13 | 2017-12-14 | 질랜드 파마 에이/에스 | Acylated glucagon analogues |
| JP2013517307A (en) * | 2010-01-20 | 2013-05-16 | ジーランド ファーマ アクティーゼルスカブ | Heart disease treatment |
| UY33462A (en) * | 2010-06-23 | 2012-01-31 | Zealand Pharma As | GLUCAGON ANALOGS |
-
2012
- 2012-12-19 IN IN4401CHN2014 patent/IN2014CN04401A/en unknown
- 2012-12-19 US US13/720,041 patent/US20130316941A1/en not_active Abandoned
- 2012-12-19 WO PCT/EP2012/076137 patent/WO2013092703A2/en not_active Ceased
- 2012-12-19 EA EA201490982A patent/EA201490982A1/en unknown
- 2012-12-19 HK HK15101109.9A patent/HK1200369A1/en unknown
- 2012-12-19 AP AP2014007797A patent/AP2014007797A0/en unknown
- 2012-12-19 BR BR112014015681A patent/BR112014015681A2/en not_active IP Right Cessation
- 2012-12-19 JP JP2014547973A patent/JP2015502380A/en active Pending
- 2012-12-19 CA CA2858949A patent/CA2858949A1/en not_active Abandoned
- 2012-12-19 MX MX2014007120A patent/MX2014007120A/en unknown
- 2012-12-19 SG SG11201403377QA patent/SG11201403377QA/en unknown
- 2012-12-19 PE PE2014000970A patent/PE20142113A1/en not_active Application Discontinuation
- 2012-12-19 CN CN201280063090.8A patent/CN104144696A/en active Pending
- 2012-12-19 AU AU2012357739A patent/AU2012357739A1/en not_active Abandoned
- 2012-12-19 KR KR1020147020623A patent/KR20140114845A/en not_active Withdrawn
- 2012-12-19 EP EP12816470.4A patent/EP2793931A2/en not_active Withdrawn
-
2014
- 2014-05-21 TN TNP2014000224A patent/TN2014000224A1/en unknown
- 2014-05-26 IL IL232800A patent/IL232800A0/en unknown
- 2014-06-11 PH PH12014501336A patent/PH12014501336A1/en unknown
- 2014-07-09 AP AP2014007774A patent/AP2014007774A0/en unknown
- 2014-07-11 MA MA37205A patent/MA35864B1/en unknown
-
2016
- 2016-08-17 US US15/239,154 patent/US20160347813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20142113A1 (en) | 2014-12-03 |
| AP2014007797A0 (en) | 2014-07-31 |
| EA201490982A1 (en) | 2015-01-30 |
| IL232800A0 (en) | 2014-07-31 |
| IN2014CN04401A (en) | 2015-09-04 |
| MA35864B1 (en) | 2014-12-01 |
| AP2014007774A0 (en) | 2014-07-31 |
| WO2013092703A2 (en) | 2013-06-27 |
| US20160347813A1 (en) | 2016-12-01 |
| SG11201403377QA (en) | 2014-07-30 |
| US20130316941A1 (en) | 2013-11-28 |
| AU2012357739A1 (en) | 2014-07-03 |
| WO2013092703A3 (en) | 2013-11-14 |
| BR112014015681A2 (en) | 2019-09-24 |
| CA2858949A1 (en) | 2013-06-27 |
| KR20140114845A (en) | 2014-09-29 |
| TN2014000224A1 (en) | 2015-09-30 |
| CN104144696A (en) | 2014-11-12 |
| EP2793931A2 (en) | 2014-10-29 |
| MX2014007120A (en) | 2015-03-05 |
| HK1200369A1 (en) | 2015-10-09 |
| JP2015502380A (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501336A1 (en) | Glucagon analogues | |
| TN2012000567A1 (en) | Glucagon analogues | |
| TN2012000560A1 (en) | Glucagon analogues | |
| PH12015500531A1 (en) | Glucagon analogues | |
| MY188182A (en) | Acylated glucagon analogues | |
| MX2011006315A (en) | Glucagon analogues. | |
| MX2016004907A (en) | Glucagon analogues. | |
| MY160219A (en) | Glucagon analogues | |
| MX2011006320A (en) | Glucagon analogues. | |
| MX2011006314A (en) | Glucagon analogues. | |
| PH12016500675A1 (en) | Acylated glucagon analogues | |
| MX2016013243A (en) | Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4. | |
| MX2016013244A (en) | Exendin-4 derivatives as peptidic dual glp-1 / glucagon receptor agonists. | |
| MX2014015423A (en) | Exendin-4 peptide analogues. | |
| MX2016013248A (en) | Dual glp-1 / glucagon receptor agonists derived from exendin-4. | |
| NZ612297A (en) | Glucagon analogs exhibiting gip receptor activity | |
| DK2158214T3 (en) | Glucagon analogues | |
| EP3922260A3 (en) | Insulin receptor partial agonists and glp-1 analogues | |
| MX2017012864A (en) | Acylated glucagon analogue. | |
| WO2014193837A8 (en) | Synthesis of galanal compounds and analogues thereof | |
| TN2011000667A1 (en) | Acylated glucagon analogues | |
| CO6382136A2 (en) | GLUCAGON ANALOGS |